Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for ...
India should focus on enhancing local vaccine manufacturing and research for better control over safety, according to GTRI. They also suggest investigating adverse health events post-vaccination to ...
Hosted on MSN1d
Which High-Risk Patients Should Get the RSV Vaccine?All three RSV vaccines -- GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA -- are FDA-approved for all adults age 60 and ...
Donald Trump’s electoral victory has shaken the market, mostly in a good way. The S&P 500 gained 5% in the first two days ...
Hosted on MSN2d
Should Kids Get the COVID-19 Vaccine?Children aged 6 months and older may need one to three doses of either vaccine, depending on their age and vaccination status ...
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback